

Ref: MHL/Sec&Legal/2024-25/92

February 04, 2025

To,
BSE Limited
Scrip Code: 542650

National Stock Exchange of India Ltd.
Scrip Symbol: METROPOLIS

Dear Sir/ Madam,

Sub: Press Release

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith is the Press Release as mentioned below:

“Metropolis Healthcare’s PAT up by 15.3% in Q3FY25”

You are requested to take the above information on record.

Thanking you,
Yours faithfully,

For **Metropolis Healthcare Limited**

Kamlesh C Kulkarni
Head – Legal & Secretarial

Encl: A/a




Press Release

Metropolis Healthcare’s PAT up by 15.3% in Q3FY25.

*~ EBITDA grows 17.8%, PAT Up 26.5% YoY in 9MFY25, driven by high operating leverage~
 ~Significant growth in Revenue Per Test (RPT), driven by higher contributions from TruHealth and Specialty segments, highlighting our focus on high-value offerings.~*

Q3FY25:



Mumbai, India, 4th February 2025: Ameera Shah-led Metropolis Healthcare Limited (**NSE: METROPOLIS | BSE: 542650**), India’s second-largest and most respected pathology laboratory chain, today announced its unaudited consolidated financial results for the quarter ended December 31st, 2024.

Q3 FY25 Key Financial Highlights

- **Strong B2C Revenue growth at 15% YoY in Q3FY25;** Patient volume grew by 5%, with a robust 10% increase in RPP (Revenue Per Patient), enabled by enhanced upselling and value delivery.
- **B2B revenue grew 10% YoY in Q3FY25** – consistent double -digit growth, third quarter in a row.
- **TruHealth revenue grew 25% YoY**, with its contribution rising from 14% in Q3FY24 to 17% in Q3FY25.
- **Specialty revenue grew 13% YoY**, driven by a focus on specialized, non-seasonal tests.
- **Reported EBITDA and PAT Margins for Q3FY25** stood at 22.2% and 9.8% respectively.

“The diagnostics industry is undergoing a paradigm shift towards personalized medicine, genomics-driven testing, and preventive healthcare, fueled by advancements in molecular diagnostics, AI, and next-generation sequencing. At Metropolis, we remain at the forefront of this transformation, leveraging deep scientific expertise and consumer insights to drive innovation and expand access to cutting-edge diagnostics.

Our strategic acquisition of Core Diagnostics is a pivotal step in this direction, strengthening our oncology and molecular diagnostics portfolio and reinforcing our commitment to becoming India’s leading cancer testing provider. As part of our long-term strategy, we are expanding our presence in North India through a ‘string of pearls’ approach, focusing on acquiring high-performing B2C businesses that are leaders in their cities, with strong EBITDA, ROCE, and cash flows. This strategy will enhance our capabilities and deepen our footprint in the region, driving long-term value creation and solidifying Metropolis’ leadership in the evolving diagnostics landscape.” ~ **Ameera Shah, Executive Chairperson & Whole-time Director, Metropolis Healthcare Limited.**

“We have achieved double-digit growth for the third consecutive quarter, despite a traditionally challenging Q3 with lower illness-driven demand. This success stems from our focus on key segments, TruHealth and Specialty, and our efforts to drive regional growth through targeted micro-marketing strategies and deeper market penetration. Through TruHealth™ packages, we have been able to enhance the customer experience by integrating home-based ECG services, vital checks, and consultations. Additionally, the introduction of AI-powered MetAdvisor recommendation engine further personalises care by analysing historical data and test combinations.

With strong partnerships and an expanding network, we remain committed to addressing regional healthcare needs and driving sustainable growth. Our continued investments in technology and service excellence will deliver lasting value to customers and stakeholders." ~ **Surendran Chemmenkotil, Chief Executive Officer, Metropolis Healthcare Limited.**

| In INR Crs. | Q3FY25 | Q3FY24 | Y-o-Y (%) |
|-----------------------------|--------|--------|-----------|
| Revenue from Operations | 323 | 291 | 10.9% |
| Reported EBITDA | 72 | 66 | 9.4% |
| Reported EBITDA Margins (%) | 22.20% | 22.50% | |
| Profit After Tax | 31 | 27 | 15.3% |
| PAT Margin (%) | 9.8% | 9.4% | |

About Metropolis Healthcare Limited: Established in 1981, Metropolis Healthcare Limited is India’s second-largest diagnostic chain, led by visionary leader Ms. Ameera Shah. With over four decades of excellence, Metropolis has been a pioneer in delivering best-in-class diagnostic services to patients, healthcare providers, and corporates across India and Africa. The company’s extensive footprint spans 22 states, 3 Union Territories, and over 700 towns in India, supported by a robust network of more than 200 laboratories, 4,400 patient service centers, and over 10,000 touchpoints. Each year, Metropolis serves millions of individuals by providing actionable health insights that empower better clinical outcomes. Metropolis offers a comprehensive range of more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company’s commitment to quality and accuracy is reinforced by its consistent CAP proficiency score of over 98% for the past decade, placing it among the top 1% of laboratories worldwide for quality assurance. The Metropolis philosophy is built on the pillars of technological superiority, a warm, patient-centric approach, and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#)

Safe harbor statement: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For further details please contact:

| | |
|---|---|
| Company: Metropolis Healthcare Ltd. CIN -L73100MH2000PLC192798 Mr. Jeyasingh Balakrishnan Head - Corporate Communications jeyasingh.b@metropolisindia.com | Investor Relations Advisors: Strategic Growth Advisors Pvt. Ltd. CIN: U74140MH2010PTC204285 Mr. Shogun Jain / Mr. Sagar Shroff +91 77383 77756 / +91 98205 19303 shogun.jain@sgapl.net / sagar.shroff@sgapl.net |
|---|---|